Zongertinib is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zongertinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zongertinib overview
Zongertinib (BI-1810631) is under development for the treatment of advanced or metastatic solid tumors and non-squamous non-small cell lung cancer, colorectal cancer, bile duct cancer (cholangiocarcinoma), esophageal cancer with HER2 mutations, HER2 positive breast cancer, gastric cancer, gastroesophageal junction carcinoma. It is administered orally. The drug candidate acts by targeting HER2 exon20.
Boehringer Ingelheim International overview
Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers an array of products including human diseases, animal health care products, and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases, among others. It also offers animal healthcare products for swine, ruminant, poultry, horses, and pets, among others. Boehringer is headquartered in Ingelheim am Rhein,Rhineland-Palatinate, Germany.
For a complete picture of Zongertinib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.